CDK13-Mediated Cell Cycle Disorder Promotes Tumorigenesis of High HMGA2 Expression Gastric Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cell Cycle Regulation

Background:

• CDK4/6 inhibitors are used for cancers with G0/G1 acceleration.
• Gastric cancer (GC) shows abnormal cell cycle molecules, but CDK4/6 inhibition is often ineffective.
• HMGA2's role in GC progression and its relationship with cell cycle phases require further investigation.

Purpose of the Study:

• To investigate the role of HMGA2 in gastric cancer progression.
• To identify HMGA2's direct target genes involved in cell cycle regulation.
• To evaluate the therapeutic potential of targeting HMGA2 and CDK13 in GC.

Main Methods:

• Analysis of 200 pairs of GC and adjacent tissues.
• Gene expression analysis to determine HMGA2 and CDK13 correlation.
• Assessment of a novel CDK12/13 inhibitor (SR-4835) in high HMGA2-expressing GC models.

Main Results:

• HMGA2 accelerates the S-G2/M phase transition in GC, unlike the G0/G1 phase targeted by CDK4/6 inhibitors.
• CDK13 was identified as a direct target gene of HMGA2.
• A positive correlation between HMGA2 and CDK13 expression was observed in GC tissues.
• High co-expression of HMGA2 and CDK13 predicts a poorer GC prognosis.
• Simultaneous inhibition of HMGA2 and CDK13 using SR-4835 showed a positive therapeutic effect in high HMGA2-expressing GC.

Conclusions:

• HMGA2 promotes GC by driving the S-G2/M cell cycle transition.
• The HMGA2-CDK13 axis is a critical driver in GC and a potential therapeutic target.
• Simultaneous inhibition of HMGA2 and CDK13 represents a novel and effective strategy for treating high HMGA2-expressing GC.
• Assessing HMGA2 and CDK13 expression can aid in predicting GC prognosis.